SIGLEC1 and hepatocellular carcinoma: We have shown that the abundance of CD169+ tumor-associated macrophages is correlated with good patient outcomes in hepatocellular carcinoma (HCC) and gastric cancer (Zhang Y. et al., 2016; Li et al., 2017).